Ascentage Pharma Group International – Unsponsored ADR (AAPG) – What Are Brokerages Thinking About This Stock?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) has been assigned a consensus rating of “Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat reports. Eleven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $43.44.

A number of research firms recently weighed in on AAPG. Citizens Jmp assumed coverage on shares of Ascentage Pharma Group International in a report on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 target price for the company. JPMorgan Chase & Co. decreased their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. William Blair assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, October 16th. They set an “outperform” rating for the company. BTIG Research reiterated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, Citigroup assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, October 14th. They set a “buy” rating and a $46.00 price target for the company.

Ascentage Pharma Group International Price Performance

NASDAQ AAPG opened at $15.36 on Tuesday. The stock’s 50 day moving average is $15.52 and its 200 day moving average is $19.83. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.22 and a quick ratio of 1.18. Ascentage Pharma Group International has a 12 month low of $13.46 and a 12 month high of $34.50.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The company had revenue of $22.24 million for the quarter. On average, research analysts expect that Ascentage Pharma Group International will post -2.43 EPS for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.